OJEMDA Drug Patent Profile

« Back to Dashboard

Which patents cover Ojemda, and what generic alternatives are available?

Ojemda is a drug marketed by Day One Biopharms and is included in two NDAs. There are two patents protecting this drug.

The generic ingredient in OJEMDA is tovorafenib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the tovorafenib profile page.

DrugPatentWatch^® Generic Entry Outlook for Ojemda

Ojemda will be eligible for patent challenges on April 23, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 23, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for OJEMDA

US Patents:	2
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Patent Applications:	349
What excipients (inactive ingredients) are in OJEMDA?	OJEMDA excipients list
DailyMed Link:	OJEMDA at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for OJEMDA

Constraining patent/regulatory exclusivity:

10,426,782

NDA:

218033

Dosage:

FOR SUSPENSION;ORAL

Constraining patent/regulatory exclusivity:

10,426,782

NDA:

217700

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for OJEMDA

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 3A Inducers Type II RAF Kinase Inhibitors

US Patents and Regulatory Information for OJEMDA

OJEMDA is protected by two US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,426,782.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Day One Biopharms	OJEMDA	tovorafenib	FOR SUSPENSION;ORAL	218033-001	Apr 23, 2024		RX	Yes	Yes	8,293,752		Y	Y
Day One Biopharms	OJEMDA	tovorafenib	TABLET;ORAL	217700-001	Apr 23, 2024		RX	Yes	Yes
Day One Biopharms	OJEMDA	tovorafenib	FOR SUSPENSION;ORAL	218033-001	Apr 23, 2024		RX	Yes	Yes

International Patents for OJEMDA

When does loss-of-exclusivity occur for OJEMDA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Brazil

Canada

China

Colombia

Costa Rica

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Japan

Morocco

Peru

Spain

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OJEMDA around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	112016022219
Canada	2943808	FORMULATION PHARMACEUTIQUE D'UN INHIBITEUR DE LA KINASE PAN-RAF, SES PROCEDES DE PREPARATION, ET PROCEDES D'UTILISATION (PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE)
China	106456787	PAN-RAF激酶抑制剂的医药调配物、其制备方法以及使用方法 (Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use)

OJEMDA (tazemetostat) Market Dynamics and Financial Trajectory: Pricing, Uptake, Competition, and Exclusivity Timeline

Last updated: July 23, 2026

Executive summary: OJEMDA (tazemetostat) has a narrow label tied to specific oncology settings, and its commercial trajectory is driven by (1) ongoing penetration into approved patient subsets, (2) competitor positioning in those same disease spaces, and (3) future patent and exclusivity timing that determines entry risk from generics and biosimilar-style substitutes (where applicable). Revenue momentum is therefore less dependent on broad-spectrum demand and more dependent on durable share in defined indications, formulary access, and payer coverage in the presence of alternative targeted agents.

---

What is OJEMDA’s approved use and how does label scope shape revenue potential?

OJEMDA is marketed as tazemetostat, an inhibitor of EZH2 (enhancer of zeste homolog 2). OJEMDA’s market dynamics are constrained by the specificity of its approved indications, which in turn affects addressable incidence, guideline uptake, and payer willingness to cover high-cost targeted therapy.

Which indications drive demand and what does that imply for uptake

Revenue is typically paced by:

• Diagnosis rate in the approved subset (how many patients meet inclusion criteria).
• Line of therapy placement (first-line vs later-line).
• Physician treatment behavior in competing regimens.
• Coverage criteria and prior authorization friction.

Key market implication: For tightly defined oncology indications, OJEMDA’s commercial growth depends on a small number of converting sites of care (major cancer centers, high-volume community oncology groups). That concentrates contracting leverage and increases the importance of outcomes in managed-care negotiations.

How does dosing and administration affect health-system demand

Oral targeted oncology drugs tend to have:

• Lower administration overhead than infusion-only regimens
• Different adherence patterns
• Different start-up friction (training is lower than for IV drugs)

OJEMDA’s financial trajectory therefore tends to track payer acceptance and patient persistence more than infusion-capacity constraints.

---

How do pricing, payer coverage, and net price dynamics affect OJEMDA revenue?

For specialty oncology therapies, top-line growth is commonly decoupled from list price changes because net price is dominated by rebates, access rules, and contract structure.

What drives net revenue for high-cost specialty oncology

Net pricing is usually a function of:

• Rebate programs tied to patient coverage and formulary status
• 340B and institution-specific purchasing
• State Medicaid / commercial carve-outs
• Contracting with PBMs and large group purchasing organizations

Financial trajectory implication: OJEMDA’s revenue curve is likely to show a “step” behavior after major formulary wins or after payer coverage guidance tightens/loosens. Without broad label expansion, these access events can matter more than incremental demand growth.

What does a narrow indication mean for contracting strategy

Narrow indication oncology products usually negotiate:

• Evidence-based prior authorization
• Specialty pharmacy routing
• Outcomes reporting or restricted coverage tiers

This tends to slow adoption in less familiar sites and can create geographic heterogeneity in prescribing.

---

What patents protect OJEMDA and what is the exclusivity timeline?

Critical driver: the timing of patent expiration and data exclusivity (and any regulatory exclusivities) governs generic entry risk and therefore the long-run revenue floor.

How to evaluate OJEMDA’s exclusivity stack

A robust exclusivity/patent estate typically includes:

• Active ingredient composition patents
• Pharmaceutical compositions (formulations)
• Methods of use (specific indications, patient groups, dosing regimens)
• Manufacturing/process patents
• Pediatric exclusivity (if applicable), and regulatory data exclusivity

Market impact: As exclusivity narrows, the financial trajectory becomes increasingly dependent on line-extension tactics, evidence generation, and competitive differentiation.

No reliable, complete patent-by-patent dataset for OJEMDA is included in the available information in this request, so an exact expiration-by-jurisdiction exclusivity timeline cannot be produced here.

---

When does OJEMDA lose exclusivity and what generic entry risks exist?

Generic entry risk is a function of:

• Whether Orange Book-listed patents are still in force
• Whether Paragraph IV filings are pending or likely
• Whether formulation or method-of-use barriers remain
• Whether the label is broad enough for “skinny” entry

Key market dynamic: For oncology drugs with method-of-use coverage, even when composition patents expire, remaining use patents can delay “full” substitution by restricting therapeutic interchange.

No Orange Book or litigation dataset is provided in the prompt, so exact dates and entry scenarios cannot be stated.

---

What is the Orange Book status of OJEMDA?

Orange Book status determines:

• Which patents are listed for each strength and dosage form
• Patent expiration dates
• Whether there are multiple patent clusters expiring at different times
• Whether any patents are vulnerable to Paragraph IV challenges

The prompt does not provide Orange Book listings for OJEMDA, so the Orange Book status cannot be stated accurately.

---

What patent litigation affects OJEMDA and how do settlements change timelines?

For specialty oncology products, litigation affects:

• Entry timing for generics
• Design-around strategies (different salt/polymorph/formulation)
• Whether ANDA sponsors receive negotiated launch dates

Typical settlement effects:

• “No earlier than” launch dates
• Patent carve-outs
• Agreement terms that can move entry by years

No litigation docket or settlement record for OJEMDA is included in the request, so litigation effects cannot be quantified.

---

How does OJEMDA compare with competing EZH2 inhibitors and other oncology regimens in the same patient subsets?

OJEMDA’s competition depends on the disease context:

• In EZH2-driven malignancies, competition can include other EZH2 pathway agents (if approved) or agents competing through trial-proven outcomes.
• In broader oncology settings where EZH2 inhibition is one option among several, OJEMDA competes with:
  • targeted therapies
  • immunotherapies
  • chemotherapy backbone regimens
  • CAR-T or cell therapies (in hematologic settings where applicable)

What matters for share capture

Share depends on:

• Response rate depth and durability
• Tolerability profile
• Treatment-switching behavior after failure of first-line therapies
• Sequencing evidence and guideline adoption

Financial trajectory implication: Without label expansion, OJEMDA’s growth is usually capped by how well it displaces established regimens and how consistently it clears access hurdles.

---

How do FDA regulatory events influence OJEMDA adoption and forecasting?

Forecasting for oncology drugs is sensitive to:

• New indication approvals
• Label expansions or restrictions
• Safety communications
• Postmarketing study readouts
• Companion diagnostic requirements (if applicable)

Commercial effect of label change

• Expanded label can broaden prescriber addressable population.
• Label restrictions can reduce eligible patients and shift competitive share.

No specific FDA milestone timeline for OJEMDA is included in the request, so milestone-by-milestone financial impact cannot be stated.

---

What manufacturing and supply constraints affect OJEMDA revenue?

For small-molecule oral oncology drugs, manufacturing risk often centers on:

• Active pharmaceutical ingredient (API) supply continuity
• Scale-up and batch consistency
• Stability and packaging for oral solids
• Quality system changes that can trigger delayed releases

Financial trajectory implication: supply disruptions tend to show up quickly in pharmacy fill rates and can lead to payer re-contracting if chronic. The longer-term risk is not stockouts alone but loss of confidence in future continuity.

No supply-chain or manufacturing event record for OJEMDA is provided in the prompt.

---

Revenue trajectory: what financial patterns should investors expect for OJEMDA?

Without company-reported revenue figures in the prompt, the analysis must focus on the governing mechanics typical for narrow-indication specialty oncology drugs.

Expected revenue shape

Common patterns:

• Ramp phase: early adoption, payer friction, and center-of-excellence prescribing
• Normalization: improving access and consistent prescribing patterns
• Plateau or step-up: label expansions, new line-of-therapy adoption, or competitive displacement
• Late-stage pressure: exclusivity narrowing, new competitor introductions, and tightening access rules

Sensitivity drivers for OJEMDA forecast

• Speed of formulary conversion in major accounts
• Patient persistence for oral regimens
• Outcomes data that influences payer renewal criteria
• Competitive trial results that shift guideline recommendations

---

Key competitive and IP risks that can shift OJEMDA’s financial trajectory

1) Competitive substitution risk

• New entrants with better tolerability or superior outcomes
• Sequencing changes supported by trial data
• Formulary switches driven by PBM contracting pressure

2) IP and regulatory substitution risk

• Orange Book patent expiration clusters
• Successful design-arounds by ANDA applicants
• Method-of-use patent barriers that either hold or fail

Exact IP risk timing cannot be quantified without an Orange Book and patent dataset.

---

Key Takeaways

• OJEMDA’s revenue trajectory is primarily governed by narrow indication demand, payer access, and competitive positioning within defined oncology patient subsets.
• Financial growth typically shows step changes around formulary wins and label/access shifts rather than smooth broad-market expansion.
• The long-run revenue floor depends on the strength and timing of the patent and exclusivity estate and on whether method-of-use and formulation barriers delay substitution.
• Exact exclusivity/Orange Book dates and litigation-driven launch risk cannot be provided from the information present in this request.

---

FAQs

1. How does narrow oncology indication scope affect OJEMDA’s patient access and revenue growth rate?
2. What PBM contracting structures most influence net price for specialty oral oncology drugs like OJEMDA?
3. How do method-of-use patents delay generic substitution even after composition patent expiry?
4. What FDA label expansions would most likely increase OJEMDA’s addressable market?
5. How do competitive outcomes trial readouts typically change prescribing and payer coverage for EZH2-inhibition therapies?

---

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.

DrugChatter Q&A for OJEMDA

Ojemda europe?
How does ojemda treat gliomas?